本帖最后由 老马 于 2013-3-13 13:43 编辑
$ n- V" [. y- `# }2 ]/ t5 [
; O% x% q# Y5 `& x健择（吉西他滨）+顺铂+阿瓦斯汀+ M O n( V) y# Z1 @9 J& e- C
Gemzar +Cisplatin + Avastin" q8 c$ G/ F/ i
http://annonc.oxfordjournals.org/content/21/9/1804.full3 b& ?6 V, u/ O' ` K. _3 I
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ) j" ~% n$ R! P3 w0 |, \. h
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; t1 F3 x1 O& q wResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ' M" {9 N, Z( f& y" H5 t" Z
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1025)
! n; V2 z( l3 v# t2 r* f华为网盘附件：) ~' t" o# w6 y, ~- Y4 c
【华为网盘】ava.JPG
$ P9 k' e) b5 `2 C |
显身卡
